REFERENCES
1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013;65:1-11.
2. Hilhorst M, van Paassen P, Tervaert JW. Limburg Renal Registry. Proteinase 3-ANCA vasculitis versus myeloperoxidase-anca vasculitis. J Am Soc Nephrol 2015;26:2314-27.
3. Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012;367:214-23.
4. Quartuccio L, Treppo E, Valent F, De Vita S. Healthcare and economic burden of ANCA-associated vasculitis in Italy: an integrated analysis from clinical and administrative databases. Intern Emerg Med 2021;16:581-9.
5. Geetha D, Jefferson JA. ANCA-associated vasculitis: core curriculum 2020. Am J Kidney Dis 2020;75:124-37.
6. Geetha D, Jin Q, Scott J, et al. Comparisons of guidelines and recommendations on managing antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int Rep 2018;3:1039-49.
7. Jennette JC, Falk RJ, Gasim AH. Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis. Curr Opin Nephrol Hypertens 2011;20:263-70.
8. Treppo E, Binutti M, Agarinis R, De Vita S, Quartuccio L. Rituximab induction and maintenance in ANCA-associated vasculitis: state of the art and future perspectives. J Clin Med 2021;10:3773.
9. Jayne DRW, Merkel PA, Schall TJ, Bekker P. ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 2021;384:599-609.
